| oxaliplatin / Generic mfg. |
| Terminated | 3 | 263 | Europe | Oxaliplatin, gemcitabine, cisplatin, lipiodol | Assistance Publique - Hôpitaux de Paris | Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular, Recurrence, Neoplasm Recurrence, Local | 11/08 | 11/08 | | |
NCT00471965: Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients |
|
|
| Completed | 3 | 371 | RoW | Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin | Sanofi | Carcinoma, Hepatocellular | 03/10 | 03/10 | | |
SECOX, NCT01245582: Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients |
|
|
| Withdrawn | 3 | 0 | RoW | oxaliplatin (SR96669), capecitabine, sorafenib | Sanofi | Hepatic Neoplasm Malignant | 02/14 | 08/15 | | |
NCT02149771: Combination Treatment for Advanced Liver Cancer |
|
|
| Withdrawn | 3 | 0 | RoW | chemoembolization, endovascular stents implantation, iodine-125 seed strand implantation | Shanghai Zhongshan Hospital, Shanghai Municipal Science and Technology Commission | Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion | 05/16 | 09/16 | | |
NCT02220088: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial |
|
|
| Terminated | 2/3 | 79 | RoW | TAI of FOLFOX, Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin, Sorafenib | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | Hepatocellular Carcinoma | 07/18 | 07/18 | | |
